Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ying Hong, Tomoko Ishizuka, Akiko Watanabe, Masaya Tachibana, Mark Lee, Hitoshi Ishizuka, Frank LaCreta, Malaz Abutarif
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/e9cdb914f78a466084a85f5aa18226a3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!